About this Research Topic
In the past decade, radiomics, radiogenomics, and nanoparticle-based molecular imaging have become an important focus area of cancer diagnosis and therapy. The rapidly evolving fields of artificial intelligence and molecular imaging can improve early disease detection, staging, and prognosis prediction, as well as enable image-guided therapy and treatment personalization. Radiomics is used for the extraction of quantitative information from medical imaging data. Radiogenomics combines radiomics with genomic phenotypes to develop predictive models of disease prognosis and outcomes. Opportunities for combining radiomics or radiogenomics with molecular imaging are broad and can be applied to biomarker development, automated protocoling, improved image acquisition, and therapy planning.
Radiomics, radiogenomics, and nanoparticle-based molecular imaging have emerged as an evolving field in precision medicine with the ultimate goal of improved diagnosis and treatment of cancers. They are increasingly utilized in various areas of both basic and clinical cancer research. In this Research Topic, we aim to include reviews and research articles that illustrate the recent application and progress of radiomics, radiogenomics, nanoparticle-based molecular imaging, and the combination of radiomics/radiogenomics with molecular imaging. In particular, we seek to facilitate a comprehensive understanding of how tools, including artificial intelligence and nanomedicine, can transform patient management by refining diagnostic precision and tailoring treatment interventions directly to individual patient profiles. Both basic research and clinical applications are welcome.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
Radiomics, radiogenomics, and nanoparticle-based molecular imaging have emerged as an evolving field in precision medicine with the ultimate goal of improved diagnosis and treatment of cancers. They are increasingly utilized in various areas of both basic and clinical cancer research. In this Research Topic, we aim to include reviews and research articles that illustrate the recent application and progress of radiomics, radiogenomics, nanoparticle-based molecular imaging, and the combination of radiomics/radiogenomics with molecular imaging. In particular, we seek to facilitate a comprehensive understanding of how tools, including artificial intelligence and nanomedicine, can transform patient management by refining diagnostic precision and tailoring treatment interventions directly to individual patient profiles. Both basic research and clinical applications are welcome.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
Keywords: Nanomedicine, Theranostics, Cancer, Molecular Imaging, Artificial Intelligence
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
